{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:20:06Z","timestamp":1792545606148,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,5,20]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>The cancer\/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid\/round cell liposarcoma (MRCLS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1c\n              <jats:sup>259<\/jats:sup>\n              T letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01\u2013, HLA-A*02:05\u2013, and\/or HLA-A*02:06\u2013positive advanced\/metastatic NY-ESO-1\u2013expressing MRCLS. Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR). The primary end point was investigator-assessed overall response rate (ORR). Safety was assessed through adverse event (AE) reports. Correlative biomarker analyses were performed post hoc. The trial is registered at ClinicalTrials.gov (identifier:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02992743\">NCT02992743<\/jats:ext-link>\n              ).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Of 23 enrolled patients, 10 in cohort 1 and 10 in cohort 2 received lete-cel. Investigator-assessed ORR was 20% (95% CI, 2.5 to 55.6) and 40% (95% CI, 12.2 to 73.8), median duration of response was 5.3 months (95% CI, 1.9 to 8.7) and 7.5 months (95% CI, 6.0 to not estimable [NE]), and median progression-free survival was 5.4 months (95% CI, 2.0 to 11.5) and 8.7 months (95% CI, 0.9 to NE) in cohorts 1 and 2, respectively. AEs included cytokine release syndrome and cytopenias, consistent with T-cell therapy\/LDR. Post hoc correlative biomarkers showed T-cell expansion and persistence in both cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>To our knowledge, this study is the first demonstrating the clinical promise of lete-cel in HLA-\/NY-ESO-1-positive patients with advanced MRCLS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco-24-01466","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T20:59:43Z","timestamp":1737493183000},"page":"1777-1788","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":25,"title":["Letetresgene Autoleucel in Advanced\/Metastatic Myxoid\/Round Cell Liposarcoma"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02992743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-3783","authenticated-orcid":true,"given":"Sandra P.","family":"D'Angelo","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Druta","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-6668","authenticated-orcid":true,"given":"Brian A.","family":"Van Tine","sequence":"additional","affiliation":[{"name":"Washington University in St Louis, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-4137","authenticated-orcid":true,"given":"David","family":"Liebner","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-4163","authenticated-orcid":true,"given":"Scott M.","family":"Schuetze","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7779-2796","authenticated-orcid":true,"given":"William D.","family":"Tap","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Preston","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1120-751X","authenticated-orcid":true,"given":"Sophia","family":"Goodison","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimson W.","family":"D'Souza","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet S.","family":"Kapoor","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Suchindran","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-9951","authenticated-orcid":true,"given":"Stefan","family":"Zajic","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Kaczynski","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaegil","family":"Kim","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Klohe","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Corigliano","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Eleftheriadou","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-4482","authenticated-orcid":false,"given":"Michael J.","family":"Nathenson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":true,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","first-page":"8","article-title":"Overview of liposarcomas and their genomic landscape","volume":"3","author":"Keung EZ","year":"2019","unstructured":"Keung EZ, Somaiah N: Overview of liposarcomas and their genomic landscape. J Transl Genet Genom 3:8, 2019","journal-title":"J Transl Genet Genom"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22720"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27847"},{"key":"e_1_3_10_5_2","unstructured":"Orphanet: Myxoid\/round cell liposarcoma. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=EN&data_id=14540&Disease_Disease_Search_diseaseGroup=liposarcoma&Disease_Disease_Search_diseaseType=Pat&Disease(s)\/group%20of%20diseases=Myxoid-round-cell-liposarcoma&title=Myxoidround%20cell%20liposarcoma&search=Disease_Search_Simple"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20478"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-2-2"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000524939"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2422"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70098-7"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.012"},{"key":"e_1_3_10_13_2","first-page":"107","article-title":"The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid\/round cell liposarcoma patients","volume":"17","author":"Pollack SM","year":"2018","unstructured":"Pollack SM: The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid\/round cell liposarcoma patients. Expert Rev Vaccines 17:107-114, 2018","journal-title":"Expert Rev Vaccines"},{"key":"e_1_3_10_14_2","unstructured":"National Cancer Institute: Myxoid\/round cell liposarcoma. https:\/\/www.cancer.gov\/pediatric-adult-rare-tumor\/rare-tumors\/rare-soft-tissue-tumors\/myxoid-round-cell-liposarcoma"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5865"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3039"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32117"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27446"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.155"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0762-2"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32491-x"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"e_1_3_10_27_2","unstructured":"U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research: Long term follow-up after administration of human gene therapy products: Guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products"},{"key":"e_1_3_10_28_2","unstructured":"U.S. Department of Health and Human Services; Food and Drug Administration; Center for Biologics Evaluation and Research: Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up: Guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006930"},{"key":"e_1_3_10_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_3_10_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_3_10_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_10_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1"},{"key":"e_1_3_10_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2"},{"key":"e_1_3_10_36_2","first-page":"A628","article-title":"Post-hoc analysis from two phase I\/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression","volume":"10","author":"Klohe E","year":"2022","unstructured":"Klohe E, Suchindran S, Kapoor G, et al: Post-hoc analysis from two phase I\/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression. J Immunother Cancer 10:A628-A629, 2022","journal-title":"J Immunother Cancer"},{"key":"e_1_3_10_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.11500"},{"key":"e_1_3_10_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0898"},{"key":"e_1_3_10_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2500"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-01466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:00:34Z","timestamp":1747346434000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-01466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,5,20]]}},"alternative-id":["10.1200\/JCO-24-01466"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-01466","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"2024-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}